Results 61 to 70 of about 80,027 (384)
The Comparative Pharmacology of Angiotensin II Receptor Antagonists
Blood Pressure, 2001 Several orally active non-peptide angiotensin II subtype 1 (AT1) receptor antagonists are now available for the treatment of hypertension. These agents have a common mechanism of action--blockade of the binding of angiotensin II to the subtype 1 receptor--and their binding to this receptor is generally insurmountable. There are some pharmacokinetic and
Michel Burnier, Marc Maillard
openaire +3 more sources
Pharmacological effects of raas blockade in ischemic nephropathy [PDF]
, 2016 Background: The management of ischemic nephropathy due to atherosclerotic renal artery stenosis has become increasingly conservative in the modern era, with current guidelines recommending optimized medical therapy as the initial step.
Barbano, Biagio +8 more
core +1 more source
Advanced Science, EarlyView.The Semaphorin 3E (Sema3E)‐Plexin‐D1 pathway mediated by C/EBPα and C/EBPβ downstream of the luteinizing hormone (LH) surge plays important roles in the mouse preovulatory ovary. Timely activation and suppression of this pathway during the preovulatory stage are crucial for ovulation, corpus luteum formation, and proper angiogenesis.
Hanxue Zhang +11 more
wiley +1 more source
Suppression of Aldosterone Synthesis and Secretion by Channel Antagonists
International Journal of Endocrinology, 2012 Aldosterone, a specific mineralocorticoid receptor (MR) agonist and a key player in the development of hypertension, is synthesized as a final product of renin-angiotensin-aldosterone system.
Keiichi Ikeda +4 more
doaj +1 more source
Endothelin-1 Drives Epithelial-Mesenchymal Transition In Hypertensive Nephroangiosclerosis [PDF]
, 2016 BACKGROUND: Tubulointerstitial fibrosis, the final outcome of most kidney diseases, involves activation of epithelial mesenchymal transition (EMT). Endothelin‐1 (ET‐1) activates EMT in cancer cells, but it is not known whether it drives EMT in the kidney.
Belloni, Anna S +13 more
core +1 more source
Advanced Science, EarlyView.A new amphipathic molecule, S416 is discovered, that locks the SARS‐CoV‐2 spike protein in its closed state, blocking viral entry. S416 acts as a molecular bolt, binding six sites: three between adjacent RBDs and three connecting NTDs to RBDs. This dual‐locking mechanism stiffens the spike structure and reduces its flexibility.
Shiliang Li +21 more
wiley +1 more source
Pharmacotherapy Review: Angiotensin Receptor Antagonists
The Journal of Clinical Hypertension, 2005 Angiotensin receptor blockers are one of several drug classes that act by interfering with activity of the renin‐angiotensin axis. Drugs in this class are as effective as angiotensin‐converting enzyme inhibitors in the reduction of blood pressure in hypertensive patients.
openaire +4 more sources
Combined TRPC3 and TRPC6 blockade by selective small-molecule or genetic deletion inhibits pathological cardiac hypertrophy [PDF]
, 2014 Chronic neurohormonal and mechanical stresses are central fea-tures of heart disease. Increasing evidence supports a role forthe transient receptor potential canonical channels TRPC3 andTRPC6 in this pathophysiology.
Andersen, Asger +13 more
core +1 more source
A Touch Enabled Hemodynamic and Metabolic Monitor
Advanced Science, EarlyView.This work presents a touch‐based hybrid platform for simultaneous monitoring of vital signs and sweat metabolites. With a simple tri‐finger touch of 4–6 min, users can concurrently get to know their glucose, uric acid, cortisol levels from fingertip sweat, along with blood pressure and heart rate.
Omeed Djassemi +19 more
wiley +1 more source
Open Access Emergency Medicine, 2010 T S Mohamed Saleem1, K Bharani1, K Gauthaman21Department of Pharmacology, Annamacharya College of Pharmacy, Rajampet-516126, Kadapa Dist, Andhra Pradesh, India; 2Department of Drug Technology, Higher Institute of Medical Technology, Derna, LibyaAbstract:
T S Mohamed Saleem +2 more
doaj